Abstract
Renal cell carcinoma (RCC) is the most common malignant tumor of the kidney and the third most common urologic cancer [12]. Since the onset of symptoms frequently occurs late and clinical signs may vary considerably, correct diagnosis is often established only when the disease is advanced. In fact, at initial presentation approximately 50% of patients already have metastatic disease [2,7,14]. The median duration of survival in patients with overt distant disease at presentation is 10 months, with a 2-year survival rate of 10%. There is no effective systemic therapy, as renal cancer has proven refractory to both hormonal treatment [13] and chemotherapy [19]. There are, however, recent preliminary reports of responses to immunotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Atzpodien J, körfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-alpha2b in advanced human malignancies. Lancet i:1509
Bassil B, Dosoretz DE, Prout GR Jr (1985) Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol 134:450–454
Busch W (1866) VI. Verhandlungen ärztlicher Gesellschaften Berl Klin Wochenschr 23:245–246
de Mulder P (1990) Are the achievements with interferon in advanced renal cell carcinoma worthwhile? 9th Congress of the European Association of Urology, June 13–16, Amsterdam
Everson TC, Cole WH (dy1966) Spontaneous regression of cancer. Saunders, Philadelphia, p 4
Fisher RI (1990) Interleukin-2, is more less or less more? The problem of dose in immunotherapy. 9th Congress of the European Association of Urology, June 13-16, Amsterdam
Giuliani L, Martorana G, Giberti C, Pesatore D, Magnani G (1983) Results of radical nephrectomy with extensive lymphadenectomy for renal cell carcinoma. J Urol 130:664–668
Graham SD Jr (1989) Immunotherapy of renal cell carcinoma. Semin Urol 7:215–227
Heicappell R, Ackermann R (1990) Rationale for immunotherapy of renal cell carcinoma. Urol Res 18:357–372
Horoszewicz JS, Murphy GP (1989) An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142:1173–1180
Oldham RK, Smalley RV (1983) Immunotherapy: the old and the new. J Biol Resp Modif 2:1–37
Paganini-Hill A, Ross RK, Henderson BE (1983) Epidemiology of kidney cancer. In: Skinner DG (ed) Urological cancer. Grune and Stratton, New York, pp 383–407
Pizzocaro G, Piva L, DiFronzo G, Giongo A, Cozzoli A, Dormia E, Minervini S, Zanollo A, Fontanella U, Longo G, Maggioni A (1987) Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 138:1379–1381
Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301
Rosenberg SA, Grimm EA, McGrogan M (1984) Biologic activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:1412–1414
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant Interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and Interleukin-2 or high-dose Interleukin-2 alone. N Engl J Med 316:889–897
Snow BW, Schellhammer PF (1982) Spontaneous regression of metastatic renal cell carcinoma. Urology 20:177–181
Yagoda A (1989) Chemotherapy of renal cell carcinoma: 1983-1989. Semin Urol 7:199–206
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ebert, T., Schmitz-Dräger, B.J., Ackermann, R. (1993). The Role of Cytokines in the Therapy of Renal Cell Carcinoma. In: Ackermann, R., Diehl, V. (eds) Malignancies of the Genitourinary Tract. Recent Results in Cancer Research, vol 126. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84583-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-84583-3_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-84585-7
Online ISBN: 978-3-642-84583-3
eBook Packages: Springer Book Archive